Viral surface and structural antigens

Viral surface and structural antigens are a diverse group of proteins that constitute the physical architecture of a virus and are essential for its life cycle. These proteins, which include envelope glycoproteins, capsid proteins, and matrix proteins, are typically the first point of contact between the virus and the host's immune system (NCBI, 2023). Their primary biological roles include mediating viral attachment to specific host cell receptors, facilitating the fusion of viral and host membranes, and protecting the viral genetic material during transmission (Nature Reviews Microbiology, 2021). In the context of infectious diseases, these antigens are the primary targets for the development of vaccines and therapeutic monoclonal antibodies, as neutralizing these proteins can effectively block the infection process (Science, 2022). From a therapeutic perspective, drugs and vaccines targeting these antigens aim to elicit or provide antibodies that bind to the viral surface, thereby preventing the virus from entering host cells or marking it for destruction by the immune system. However, the high mutation rates of many viruses, particularly RNA viruses like influenza and SARS-CoV-2, lead to antigenic drift and shift, which can result in the emergence of variants that evade existing treatments (CDC, 2022). Consequently, these antigens are also critical biomarkers used in diagnostic assays to detect the presence of a virus and monitor the efficacy of therapeutic interventions.

Other names

Viral surface proteinsViral structural proteinsEnvelope proteinsCapsid proteinsSpike proteinsMatrix proteinsViral glycoproteins

Drugs targeting these antigens primarily function by neutralizing the virus, which involves binding to surface proteins to prevent their interaction with host cell receptors or inhibiting the conformational changes required for membrane fusion and viral entry (Nature Reviews Microbiology, 2021). Additionally, some agents inhibit viral enzymes located on the surface, such as neuraminidase, to prevent the release of new virions from infected cells (NCBI, 2023).